{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:31:47Z","timestamp":1759332707096},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T00:00:00Z","timestamp":1305676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00280-011-1663-3","type":"journal-article","created":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T15:13:13Z","timestamp":1305645193000},"page":"35-42","source":"Crossref","is-referenced-by-count":24,"title":["A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer"],"prefix":"10.1007","volume":"69","author":[{"given":"Zacharenia","family":"Saridaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Kourakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristides","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Ardavanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Androulakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Kalbakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambros","family":"Vamvakas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilis","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitris","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,18]]},"reference":[{"key":"1663_CR1","first-page":"431","volume":"54","author":"HE Skipper","year":"1970","unstructured":"Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54:431\u2013450","journal-title":"Cancer Chemother Rep"},{"key":"1663_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v16i2.420","volume":"16","author":"OG Scharovsky","year":"2009","unstructured":"Scharovsky OG, Mainetti LE, Rozados VR (2009) Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol 16:7\u201315","journal-title":"Curr Oncol"},{"key":"1663_CR3","doi-asserted-by":"crossref","unstructured":"Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, Marselos M, Pavlidis N (2009) Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 15:6454\u20136461","DOI":"10.1158\/1078-0432.CCR-09-0970"},{"key":"1663_CR4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105:1045\u20131047","journal-title":"J Clin Invest"},{"key":"1663_CR5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","volume":"4","author":"RS Kerbel","year":"2004","unstructured":"Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423\u2013436","journal-title":"Nat Rev Cancer"},{"key":"1663_CR6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.1984.66","volume":"49","author":"B Hobson","year":"1984","unstructured":"Hobson B, Denekamp J (1984) Endothelial proliferation in tumours and normal tissues: continuous labelling studies. Br J Cancer 49:405\u2013413","journal-title":"Br J Cancer"},{"key":"1663_CR7","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O\u2019Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878\u20131886","journal-title":"Cancer Res"},{"key":"1663_CR8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/annonc\/mdj066","volume":"17","author":"M Colleoni","year":"2006","unstructured":"Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nole F, Viale G, Goldhirsch A (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17:232\u2013238","journal-title":"Ann Oncol"},{"key":"1663_CR9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00001813-200602000-00001","volume":"17","author":"T Lam","year":"2006","unstructured":"Lam T, Hetherington JW, Greenman J, Maraveyas A (2006) From total empiricism to a rational design of metronomic chemotherapy phase I dosing trials. Anticancer Drugs 17:113\u2013121","journal-title":"Anticancer Drugs"},{"key":"1663_CR10","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-08-2710","volume":"15","author":"EL Schwartz","year":"2009","unstructured":"Schwartz EL (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15:2594\u20132601","journal-title":"Clin Cancer Res"},{"key":"1663_CR11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","volume":"12","author":"M Marty","year":"2001","unstructured":"Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C (2001) Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12:1643\u20131649","journal-title":"Ann Oncol"},{"key":"1663_CR12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205:275\u2013292","journal-title":"J Pathol"},{"key":"1663_CR13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00280-009-1081-y","volume":"65","author":"A Jones","year":"2010","unstructured":"Jones A, O\u2019Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V (2010) Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Cancer Chemother Pharmacol 65:755\u2013763","journal-title":"Cancer Chemother Pharmacol"},{"key":"1663_CR14","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","volume":"13","author":"S Jones","year":"1995","unstructured":"Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O\u2019Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567\u20132574","journal-title":"J Clin Oncol"},{"key":"1663_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdi024","volume":"16","author":"A Welt","year":"2005","unstructured":"Welt A, von MG, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U (2005) Phase I\/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 16:64\u201369","journal-title":"Ann Oncol"},{"key":"1663_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/jco.2003.09.057","volume":"21","author":"G Freyer","year":"2003","unstructured":"Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21:35\u201340","journal-title":"J Clin Oncol"},{"key":"1663_CR17","doi-asserted-by":"crossref","unstructured":"Addeo R, Faiola V, Cannamo G, Guarrasi R, Montella L, Lodice P, Sgambato A, Capasso E, Caraglia M, Del Prete S (2009) A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: a phase II trial. J Clin Oncol 27:15s (abstract 1085)","DOI":"10.1200\/jco.2009.27.15_suppl.1085"},{"key":"1663_CR18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/cncr.21986","volume":"107","author":"J Ajani","year":"2006","unstructured":"Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221\u2013231","journal-title":"Cancer"},{"key":"1663_CR19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Schuller","year":"2000","unstructured":"Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291\u2013297","journal-title":"Cancer Chemother Pharmacol"},{"key":"1663_CR20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1634\/theoncologist.6-1-56","volume":"6","author":"JL Blum","year":"2001","unstructured":"Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6:56\u201364","journal-title":"Oncologist"},{"key":"1663_CR21","doi-asserted-by":"crossref","unstructured":"Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H (2006) Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 24:570 (abstract 570)","DOI":"10.1200\/jco.2006.24.18_suppl.570"},{"key":"1663_CR22","unstructured":"Sawada N, Fujimoto-Ouch F, Ishikawa T, Tanaka Y, Ishituka H (2002) Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 43:1088 (abstract 5388)"},{"key":"1663_CR23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1743-7563.2006.00083.x","volume":"3","author":"AJ Davis","year":"2007","unstructured":"Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland SP (2007) Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer. Asia Pac J Clin Oncol 3:37\u201343","journal-title":"Asia Pac J Clin Oncol"},{"key":"1663_CR24","first-page":"2451","volume":"26","author":"M Ghosn","year":"2006","unstructured":"Ghosn M, Kattan J, Farhat F, Younes F, Gasmi J (2006) Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 26:2451\u20132456","journal-title":"Anticancer Res"},{"key":"1663_CR25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/annonc\/mdj058","volume":"17","author":"F Nole","year":"2006","unstructured":"Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A (2006) Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 17:322\u2013329","journal-title":"Ann Oncol"},{"key":"1663_CR26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-008-0915-3","volume":"64","author":"F Nole","year":"2009","unstructured":"Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A (2009) Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 64:673\u2013680","journal-title":"Cancer Chemother Pharmacol"},{"key":"1663_CR27","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1200\/JCO.1994.12.9.1754","volume":"12","author":"EK Rowinsky","year":"1994","unstructured":"Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohneker JA, Lubejko B, Sartorius SE, Ettinger DS (1994) Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 12:1754\u20131763","journal-title":"J Clin Oncol"},{"key":"1663_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-005-0014-0","volume":"7","author":"M Markman","year":"2005","unstructured":"Markman M (2005) \u2018Flat-fixed dosing\u2019 of chemotherapy: a concept whose time has come? Curr Oncol Rep 7:1\u20132","journal-title":"Curr Oncol Rep"},{"key":"1663_CR29","unstructured":"National Cancer Institute (2003) Common toxicity criteria Vs 3.0"},{"key":"1663_CR30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1663_CR31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","volume":"15","author":"G Liu","year":"1997","unstructured":"Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15:110\u2013115","journal-title":"J Clin Oncol"},{"key":"1663_CR32","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaorative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaorative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"1663_CR33","doi-asserted-by":"crossref","unstructured":"Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, CD003372","DOI":"10.1002\/14651858.CD003372.pub3"},{"key":"1663_CR34","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.ejca.2008.07.019","volume":"44","author":"N Wilcken","year":"2008","unstructured":"Wilcken N, Dear R (2008) Chemotherapy in metastatic breast cancer: a summary of all randomised trials reported 2000\u20132007. Eur J Cancer 44:2218\u20132225","journal-title":"Eur J Cancer"},{"key":"1663_CR35","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","volume":"16","author":"R Fossati","year":"1998","unstructured":"Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439\u20133460","journal-title":"J Clin Oncol"},{"key":"1663_CR36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/jnci\/djp235","volume":"101","author":"F Cardoso","year":"2009","unstructured":"Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101:1174\u20131181","journal-title":"J Natl Cancer Inst"},{"key":"1663_CR37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273\u2013286","journal-title":"Nat Rev Drug Discov"},{"key":"1663_CR38","doi-asserted-by":"crossref","unstructured":"Schott AF, Lew D, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Linden HM, Hortobagyi GN, Livingston RB (2010) Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). J Clin Oncol 28:15s (abstract 1006)","DOI":"10.1200\/jco.2010.28.15_suppl.1006"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1663-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1663-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1663-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T09:36:57Z","timestamp":1637660217000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1663-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,18]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1663-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,18]]}}}